Emerging gram-negative infections in burn wounds

Journal of Burn Care and Research

Volumn 32, Issue 5, 2011, Pages 570-576

  Azzopardi, Ernest A ^a,b   Azzopardi, Sarah M ^c   Boyce, Dean E ^b   Dickson, William A ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Welsh Centre for Burns and Plastic Surgery   (United Kingdom)

^c MATER DEI HOSPITAL   (Malta)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN; WATER;

ACHROMOBACTER XYLOSOXIDANS; AEROMONAS HYDROPHILA; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIUM ISOLATE; BURN; BURN INFECTION; CEDECIA LAPIGEI; CHRYSEOBACTERIUM; DISEASE PREDISPOSITION; GRAM NEGATIVE INFECTION; HEALTH CARE COST; HUMAN; HYDROTHERAPY; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; STENOTROPHOMONAS MALTOPHILIA; THERMAL INJURY;

ADULT; AEROMONAS; BURNS; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; PREVALENCE; RISK FACTORS; STENOTROPHOMONAS MALTOPHILIA; UNITED STATES;

EID: 80052681726     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/BCR.0b013e31822ac7e6     Document Type: Article

References (69)

1. Urgently needed: new antibiotics. Lancet 2009;374:1868.
2. Foster S, editor. The economic burden of antibiotic resistance-evidence from three recent studies. 2010 Annual Conference on Antimicrobial Resistance, 1-3 February, 2010, Bethesda, USA.
3. Brodie L, Brodribb R, Dickson D, et al. Emergency management of severe burns. Brisbane, Australia: Australia New Zealand Burn Association; 2004.
4. Armour AD, Shankowsky HA, Swanson T, Lee J, Tredget EE. The impact of nosocomially-acquired resistant Pseudomonas aeruginosa infection in a burn unit. J Trauma 2007;63: 164-71. (Pubitemid 47057580)
5. D'Avignon L, Saffle J, Chung K, Cancio L. Prevention and management of infections associated with burns in the combat casualty. J Trauma 2008;64:S277.
6. Ansermino M, Hemsley C. Intensive care management and control of infection. BMJ 2004;329:220-3. (Pubitemid 39013283)
7. Church D, Elsayed S, Reid O, Winston B, Lindsay R. Burn wound infections. Clin Microbiol Rev 2006;19:403-34.
8. Altoparlak U, Erol S, Akcay MN, Celebi F, Kadanali A. The time-related changes of antimicrobial resistance patterns and predominant bacterial profiles of burn wounds and body flora of burned patients. Burns 2004;30:660-4. (Pubitemid 39314511)
9. Zhang LQ, Su F, Liu HY, Wu XT, Zhao HT. Survey on the distribution of burn pathogens and their antibiotic resistance in burn unit (in Chinese). Zhonghua Shao Shang Za Zhi 2007;23:349-51. (Pubitemid 350267991)
10. Clark NM, Hershberger E, Zervosc MJ, Lynch JP III. Antimicrobial resistance among gram-positive organisms in the intensive care unit. Curr Opin Crit Care 2003;9:403-12. (Pubitemid 37204796)
11. European Medicines Agency ECfDPaC. Joint technical report: the bacterial challenge-time to react; 2009.
12. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1-12.
13. Talbot GH. What is in the pipeline for Gram-negative pathogens? Expert Rev Anti Infect Ther 2008;6:39-49. (Pubitemid 351372578)
14. Morel C, Mossialos E. Stoking the antibiotic pipeline. BMJ 2010;340:c2115.
15. Mason A Jr, McManus A, Pruitt B Jr. Association of burn mortality and bacteremia: a 25-year review. Arch Surg 1986; 121:1027.
16. Greenhalgh DG, Saffle JR, Holmes JH IV, et al. American Burn Association consensus conference to define sepsis and infection in burns. J Burn Care Res 2007;28:776-90. (Pubitemid 350085032)
17. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32: 470-85.
18. Boucher HW. Challenges in anti-infective development in the era of bad bugs, no drugs: a regulatory perspective using the example of bloodstream infection as an indication. Clin Infect Dis 2010;50(Suppl 1):S4-9.
19. Peterson LR. Bad bugs, no drugs: no ESCAPE revisited. Clin Infect Dis 2009;49:992-3.
20. Phillips P, Ball C, Sacket D, et al. Oxford Centre for Evidence-based Medicine-Levels of Evidence (March 2009). Hierarchy of Evidence Levels. Oxford: University of Oxford; 2001. Available at http://www.cebm.net/index. aspx?o-1025. Accessed 2009.
21. Janda J, Abbott S. The genus Aeromonas: taxonomy, pathogenicity, and infection. Clin Microbiol Rev 2010;23:35-73.
22. Barillo DJ, McManus AT, Cioffi WG, McManus WF, Kim SH, Pruitt BA Jr. Aeromonas bacteraemia in burn patients. Burns 1996;22:48-52. (Pubitemid 26009260)
23. Phillips JA, Bernhardt HE, Rosenthal SG. Aeromonas hydrophila infections. Pediatrics 1974;53:110-2.
24. Purdue GF, Hunt JL. Aeromonas hydrophila infection in burn patients. Burns Incl Therm Inj 1988;14:220-1.
25. Abbott S, Seli L, Catino M Jr, Hartley M, Janda J. Misidentification of unusual Aeromonas species as members of the genus Vibrio: a continuing problem. J Clin Microbiol 1998; 36:1103.
26. Skoll PJ, Hudson DA, Simpson JA. Aeromonas hydrophila in burn patients. Burns 1998;24:350-3. (Pubitemid 28330412)
27. Kienzle N, Muller M, Pegg S. Aeromonas wound infection in burns. Burns 2000;26:478-82. (Pubitemid 30254181)
28. Wilcox RA, Chin GK, Segasothy M. Aeromonas hydrophila infection secondary to an electrical burn. Med J Aust 2000; 173:219-20. (Pubitemid 30658964)
29. Ampel N, Peter G. Aeromonas bacteraemia in a burn patient. Lancet 1981;2:987.
30. Ko WC, Chuang YC. Aeromonas bacteremia: review of 59 episodes. Clin Infect Dis 1995;20:1298-304.
31. Rosenthal SG, Bernhardt HE, Phillips JA III. Aeromonas hydrophila wound infection. Plast Reconstr Surg 1974;53: 77-9.
32. Ribeiro NF, Heath CH, Kierath J, Rea S, Duncan-Smith M, Wood FM. Burn wounds infected by contaminated water: case reports, review of the literature and recommendations for treatment. Burns 2009;36:9-22.
33. Lai CC, Shiao CC, Lu GD, Ding LW. Aeromonas hydrophila and Aeromonas sobria bacteremia: rare pathogens of infection in a burn patient. Burns 2007;33:255-7.
34. Sartor C, Limouzin-Perotti F, Legre R, et al. Nosocomial infections with Aeromonas hydrophila from leeches. Clin Infect Dis 2002;35:E1-5.
35. LeChevallier M, Evans T, Seidler R, et al. Aeromonas sobria in chlorinated drinking water supplies. Microb Ecol 1982;8: 325-33. (Pubitemid 13105942)
36. Scoaris D, Bizerra F, Yamada-Ogatta S, Abreu Filho B, et al. The occurrence of Aeromonas spp. in the bottled mineral water, well water and tap water from the municipal supplies. Braz Arch Biol Technol 2008;51:1049-55.
37. Kelly KA, Koehler JM, Ashdown LR. Spectrum of extraintestinal disease due to Aeromonas species in tropical Queensland, Australia. Clin Infect Dis 1993;16:574-9. (Pubitemid 23121075)
38. Yasti AC, Otan E, Doganay M, Kama NA. Aeromonas hydrophila in a burn patient. J Burn Care Res 2009;30:898-900.
39. Hernould M, Gagne S, Fournier M, Quentin C, Arpin C. Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance. Antimicrob Agents Chemother 2008;52:1559-63. (Pubitemid 351522036)
40. Singh DV, Sanyal SC. Antibiotic resistance in clinical and environmental isolates of Aeromonas spp. J Antimicrob Chemother 1994;33:368-9. (Pubitemid 24076827)
41. Chang YC, Shih DY, Wang JY, Yang SS. Molecular characterization of class 1 integrons and antimicrobial resistance in Aeromonas strains from foodborne outbreak-suspect samples and environmental sources in Taiwan. Diagn Microbiol Infect Dis 2007;59:191-7. (Pubitemid 47484127)
42. Libisch B, Giske CG, Kovacs B, Toth TG, Fuzi M. Identification of the first VIM metallo-beta-lactamase-producing multiresistant Aeromonas hydrophila strain. J Clin Microbiol 2008;46:1878-80. (Pubitemid 351657248)
43. Vila J, Marco F, Soler L, Chacon M, Figueras M. In vitro antimicrobial susceptibility of clinical isolates of Aeromonas caviae, Aeromonas hydrophila and Aeromonas veronii biotype sobria. J Antimicrob Chemother 2002;49:701-2. (Pubitemid 34428991)
44. Sader HS, Jones RN. Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. Int J Antimicrob Agents 2005;25:95-109. (Pubitemid 40138946)
45. Awan M, Maqbool A, Bari A, Krovacek K. Antibiotic susceptibility profile of Aeromonas spp. isolates from food in Abu Dhabi, United Arab Emirates. New Microbiol 2009;32: 17-23.
46. Koehler J, Ashdown L. In vitro susceptibilities of tropical strains of Aeromonas species from Queensland, Australia, to 22 antimicrobial agents. Antimicrob Agents Chemother 1993;37:905-7. (Pubitemid 23096902)
47. Chim H, Song C. Aeromonas infection in critically ill burn patients. Burns 2007;33:756-9. (Pubitemid 47248085)
48. Whitaker IS, Kamya C, Azzopardi EA, Graf J, Kon M, Lineaweaver WC. Preventing infective complications following leech therapy: is practice keeping pace with current research? Microsurgery 2009;29:619-25.
49. Whitaker IS, Elmiyeh B, Wright DJ. Hirudo medicinalis: the need for prophylactic antibiotics. Plast Reconstr Surg 2003; 112:1185-6. (Pubitemid 38251834)
50. Whitaker IS, Izadi D, Oliver DW, Monteath G, Butler PE. Hirudo Medicinalis and the plastic surgeon. Br J Plast Surg 2004;57:348-53. (Pubitemid 38735714)
51. Poirel L, Naas T, Nicolas D, et al. Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid-and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob Agents Chemother 2000;44:891-7. (Pubitemid 30165266)
52. Olsen RH, Wright CD. Interaction of Pseudomonas and Enterobacteriaceae plasmids in Aeromonas salmonicida. J Bacteriol 1976;128:228-34.
53. Davison PG, Loiselle FB, Nickerson D. Survey on current hydrotherapy use among North American burn centers. J Burn Care Res 2010;31:393-9.
54. Muder RR. Optimizing therapy for Stenotrophomonas maltophilia. Semin Respir Crit Care Med 2007;28:672-7.
55. Friedman ND, Korman TM, Fairley CK, Franklin JC, Spelman DW. Bacteraemia due to Stenotrophomonas maltophilia: an analysis of 45 episodes. J Infect 2002;45: 47-53. (Pubitemid 36104808)
56. Micozzi A, Venditti M, Monaco M, et al. Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies. Clin Infect Dis 2000;31:705-11. (Pubitemid 32295490)
57. Toro M, Rodriguez-Bano J, Herrero M, et al. Clinical epidemiology of Stenotrophomonas maltophilia colonization and infection: a multicenter study. Medicine (Baltimore) 2002; 81:228-39. (Pubitemid 34507209)
58. Jang T, Wang F, Wang L, Liu C, Liu I. Xanthomonas maltophilia bacteremia: an analysis of 32 cases. J Formos Med Assoc 1992;91:1170-6. (Pubitemid 23119826)
59. Valdezate S, Vindel A, Loza E, Baquero F, Canton R. Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical strains. Antimicrob Agents Chemother 2001; 45:1581-4. (Pubitemid 32374141)
60. Tsai WP, Chen CL, Ko WC, Pan SC. Stenotrophomonas maltophilia bacteremia in burn patients. Burns 2006;32: 155-8.
61. Leung C, Drew P, Azzopardi EA. Extended multidrugresistant Stenotrophomonas maltophilia septicemia in a severely burnt patient. J Burn Care Res 2010;31:966.
62. Dalamaga M, Karmaniolas K, Chavelas C, Liatis S, Matekovits H, Migdalis I. Stenotrophomonas maltophilia: a serious andrare complication in patients suffering from burns. Burns 2003;29:711-3. (Pubitemid 37230087)
63. English VL, Lindberg RB. Isolation of Vibrio alginolyticus from wounds and blood of a burn patient.AmJ Med Technol 1977;43:989-93.
64. Magnusson MR, Pegg SP. Vibrio cholerae non-O1 primary septicaemia following a large thermal burn. Burns 1996;22: 44-7. (Pubitemid 26009259)
65. Regules JA, Horvath LL, Chung KK. Invasive Vibrio cholerae infection following burn injury. J Burn Care Res 2008;29: 551-4. (Pubitemid 351667938)
66. Hsueh PR, Teng LJ, Yang PC, Ho SW, Hsieh WC, Luh KT. Increasing incidence of nosocomial Chryseobacterium indologenes infections in Taiwan. Eur J Clin Microbiol Infect Dis 1997;16:568-74. (Pubitemid 27417320)
67. Kienzle N, Muller M, Pegg S. Chryseobacterium in burn wounds. Burns 2001;27:179-82. (Pubitemid 32156992)
68. Dalamaga M, Karmaniolas K, Arsenis G, et al. Cedecea lapagei bacteremia following cement-related chemical burn injury. Burns 2008;34:1205-7.
69. Vu-Thien H, Darbord JC, Moissenet D, et al. Investigation of an outbreak of wound infections due to Alcaligenes xylosoxidans transmitted by chlorhexidine in a burns unit. Eur J Clin Microbiol Infect Dis 1998;17:724-6. (Pubitemid 29218996)